A phases III multicenter trial of human recombinant interleukin-1 receptor antagonist in treatment of patients with sepsis syndrome
Fisher, C.J.Jr.; Dhainaut, J.F.; Pribble, J.P.; Knaus, W.A.; Thompson, R.C.; Group, I. 1ra Phase, II.S.psis Syndrome Study
Lymphokine and Cytokine Research 12(5): 390
1993
ISSN/ISBN: 1056-5477 Accession: 029744027
Full Text Article emailed within 1 workday: $29.90
Related References
Fisher, C.J.; Slotman, G.J.; Opal, S.M.; Pribble, J.P.; Bone, R.C.; Emmanuel, G.; Ng, D.; Bloedow, D.C.; Catalano, M.A. 1994: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial Critical Care Medicine 22(1): 12-21Fisher, C.J. 1994: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase IIi rh IL-1ra Sepsis Syndrome Study Group JAMA: The Journal of the American Medical Association 271(23): 1836-1843
Fisher, C.J.; Dhainaut, J.F.; Opal, S.M.; Pribble, J.P.; Balk, R.A.; Slotman, G.J.; Iberti, T.J.; Rackow, E.C.; Shapiro, M.J.; Greenman, R.L. 1994: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase IIi rhIL-1ra Sepsis Syndrome Study Group JAMA 271(23): 1836-1843
Opal, S.M.; Fisher, C.J.; Dhainaut, J.F.; Vincent, J.L.; Brase, R.; Lowry, S.F.; Sadoff, J.C.; Slotman, G.J.; Levy, H.; Balk, R.A.; Shelly, M.P.; Pribble, J.P.; LaBrecque, J.F.; Lookabaugh, J.; Donovan, H.; Dubin, H.; Baughman, R.; Norman, J.; DeMaria, E.; Matzel, K.; Abraham, E.; Seneff, M. 1997: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. the Interleukin-1 Receptor Antagonist Sepsis Investigator Group Critical Care Medicine 25(7): 1115-1124
Noe, L.L.; Pribble, J.P.; Barriere, S.L.; Drummond, M.F.; Hout, B.A.; Bloom, B.S.; Levy, H.; Opal, S.M.; Balk, R.A. 1994: An analysis of hospital length of stay in a double-blind, placebo-controlled clinical trial of recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome Pharmacotherapy 14(3): 371
Tompkins, R.G. 1994: Human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome Critical Care Medicine 22(1): 3
Fisher, C.J.; Dhainaut, J.D.; Reines, H.D.; Shelly, M.P.; Thompson, B.W.; Labrecque, J.F.; Catalano, M.A.; Knaus, W.A.; Sadoff, J.C.; Opal, S.M.; Pribble, J.P.; Balk, R.A.; Slotman, G.J.; Iberti, T.J.; Rackow, E.C.; Shapiro, M.J.; Greenman, R.L. 1994: Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome Jama, the Journal of the American Medical Association 271(23): 1836-1843
Bresnihan, B.; Lookabaugh, J.; Witt, K.; Musikic, P. 1996: Treatment with recombinant human interleukin-1 receptor antagonist in rheumatoid arthritis Results of a randomized double-blind, placebo-controlled multicenter trial Arthritis and Rheumatism 39(9 Suppl): S73
Meyer, N.J.; Reilly, J.P.; Anderson, B.J.; Palakshappa, J.A.; Jones, T.K.; Dunn, T.G.; Shashaty, M.G.S.; Feng, R.; Christie, J.D.; Opal, S.M. 2018: Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration Critical Care Medicine 46(1): 21-28
Cohen, S.; Hurd, E.; Cush, J.; Schiff, M.; Weinblatt, M.E.; Moreland, L.W.; Kremer, J.; Bear, M.B.; Rich, W.J.; McCabe, D. 2002: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial Arthritis and Rheumatism 46(3): 614-624
Fleischmann, R.M.; Schechtman, J.; Bennett, R.; Handel, M.L.; Burmester, G-Rudiger.; Tesser, J.; Modafferi, D.; Poulakos, J.; Sun, G. 2003: Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial Arthritis and Rheumatism 48(4): 927-934
Opal, S.M.; Fisher, C.J.; Shelly, M.P.; Pribble, J.P.; Labrecque, J.F.; Lookabaugh, J.; Donovan, H.; Dubin, H.; Baughman, R.; Norman, J.; Demaria, E.; Matzel, K.; Dhainaut Jf, A.; Abraham, E.; Seneff, M.; Vincent, J.L.; Brase, R.; Lowry, S.F.; Sadoff, J.C.; Slotman, G.J. 1997: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis : A phase III, randomized, double-blind, placebo-controlled, multicenter trial Annual Educational Symposium of the new Jersey Chapter of the Society of Critical Care Medicine 25(7): 1115-1124
Bendele, A.M.; Chlipala, E.S.; Rich, W.R.; Edwards, C.K.IIi 1999: Combination benefit of treatment with recombinant human interleukin-1 receptor antagonist and pegylated recombinant human soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis Arthritis and Rheumatism 42(9 Suppl): S171
Tesser, J.; Fleischmann, R.; Dore, R.; Bennett, R.; Solinger, A.; Joh, T.; Modafferi, D.; Schechtman, J. 2004: Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis Journal of Rheumatology 31(4): 649-654
Slotman, G.J.; Friedman, B.; Brathwaite, C.; Mure, A.J.; Melhorn, L.; Shapiro, E.; Quinn, J.V. 1994: The effects of human recombinant interleukin-1 antagonist on plasma levels of eicosanoids and cytokines in patients with sepsis syndrome Chest 106(2 Suppl): 62S
Pribble, J.P.; FisherCharles, J.Jr.; Opal, S.M.; Balk, R.A.; Slotman, G.J.; Reines, H.D.; Shelly, M.P.; Dhainaut, J.F. A.; Stiles, D.M.; Sadoff, J.C.; Labrecque, J.F.; Campion, G.V.; (Usa), P., II.R. 1ra Sepsis Syndrome Study Group 1994: Recombinant human interleukin-1 receptor antagonist increases survival time in patients with sepsis-induced organ dysfunction Pharmacotherapy 14(3): 355
Boermeester, M.A.; van Leeuwen, P.A.; Schneider, A.J.; Houdijk, A.P.; Ferwerda, C.C.; Wesdorp, R.I. 1993: Interleukin-1 receptor antagonist: a new therapeutic agent in the treatment of sepsis syndrome Nederlands Tijdschrift Voor Geneeskunde 137(7): 337-342
Dhainaut, J.F.; Tenaillon, A.; Le Tulzo, Y.; Schlemmer, B.; Solet, J.P.; Wolff, M.; Holzapfel, L.; Zeni, F.; Dreyfuss, D.; Mira, J.P. 1994: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group Critical Care Medicine 22(11): 1720-1728
Gordon, G.S.; Fisher, C.F.; Slotman, G.J.; Opal, S.M.; Pribble, J.P.; Stiles, D.M.; Catalano, M.A. 1992: Cost effectiveness of treatment with interleukin 1 receptor antagonist il 1ra in patients with sepsis syndrome Clinical Research 40(2): 254A
Dhainaut, J.F.; Tenaillon, A.; Hemmer, M.; Damas, P.; Le Tulzo, Y.; Radermacher, P.; Schaller, M.D.; Sollet, J.P.; Wolff, M.; Holzapfel, L.; Zeni, F.; Vedrinne, J.M.; de Vathaire, F.; Gourlay, M.L.; Guinot, P.; Mira, J.P. 1998: Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group Critical Care Medicine 26(12): 1963-1971